Wandercraft's self-balancing exoskeleton Atalante X receives second FDA clearance, adding spinal cord injury rehabilitation indication

Wandercraft announced that its self-balancing exoskeleton Atalante X has received FDA clearance for rehabilitation training in patients with spinal cord injuries at levels T5 to L5, its second FDA clearance following approval for stroke rehabilitation in December 2022. The clearance is based on safety and efficacy data from more than 500 patients, including clinical trials and real-world evidence; Atalante X features powered ankle joint mechanisms and self-balancing technology, allowing patients to stand, walk, and step in different directions during their first training session.